Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
about
PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouseRadiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [(11)C]ME@HAPTHIA progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") miceAllopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's diseaseHuman Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine β-Hydroxylase Knockout MiceRole of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.Manganese-induced atypical parkinsonism is associated with altered Basal Ganglia activity and changes in tissue levels of monoamines in the ratβ1-Adrenergic receptors activate two distinct signaling pathways in striatal neuronsNorepinephrine is required to promote wakefulness and for hypocretin-induced arousal in zebrafish.Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors.Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing miceBehavioral phenotyping of mouse models of Parkinson's disease.Neurophysiological Changes Induced by Chronic Toxoplasma gondii InfectionEffects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications.L-DOPA reverses motor deficits associated with normal aging in mice.Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's diseaseElectro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated miceTongue force and timing deficits in a rat model of Parkinson disease.Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbensToll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons.Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivoApoptosis-inducing factor in nigral dopamine neurons: Higher levels in primates than in mice.Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling.The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalitiesSequential Loss of LC Noradrenergic and Dopaminergic Neurons Results in a Correlation of Dopaminergic Neuronal Number to Striatal Dopamine Concentration.Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant α-synuclein.Specificity and impact of adrenergic projections to the midbrain dopamine system.Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice.Light and electron microscopic localization of alpha-1 adrenergic receptor immunoreactivity in the rat striatum and ventral midbrainalpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse.Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.Advances in non-dopaminergic treatments for Parkinson's disease
P2860
Q21135297-B3526F1D-BA50-4AD7-8E0A-A87A92B60350Q21999407-CC4740FE-4B8F-4A1E-8E47-4714033B681BQ26859072-A377C5E9-041A-4272-90FE-396D4740892AQ27334826-F427D178-F553-451B-AB05-D07B79159BF6Q28115881-0E12094D-7CFC-4FFE-909C-71A93D276155Q28395100-36360507-6BD1-4FDF-B073-B2F849C87F32Q28539360-A969FCF3-7784-470B-A8FA-4FD03BBFEFD6Q28581364-D36AA1A1-4C61-4DBC-AFA6-6938893F7146Q30401043-6A97243B-CF09-46BD-AD6B-9DB00F58B7E3Q30540053-FD8B905A-4BEC-4BD6-AFAA-6F2912B1517BQ33312931-F51350FF-E058-4595-9D39-751B1253CF6AQ33507513-1BEE8303-38CA-4B9D-9B99-E8E1529A7B15Q33680232-2C297453-6406-43F0-B5F7-2D55123DEFD4Q33820609-74A1C1A7-BEF1-4AC1-B00C-0910A231BCE7Q33847259-68936EE2-B357-4998-BAAC-CB4ABE1B2D32Q33918393-FB59B28D-C411-494A-AD12-BA92964B57DCQ34391616-6791E8B7-62F5-45FE-B1B0-8B6AFE80C008Q34482342-25CFC833-FB45-4D8A-AF21-4AA14622AFE8Q34572608-6ACC5358-1047-46B2-AFB0-60390D04839AQ34758776-0CB517B5-747B-433E-BAFE-CB8C460FD221Q35041340-6EEC2F37-0D6F-4497-B6C3-5B660ABD0C09Q35065682-92C4B4E4-CEC5-4930-B2F6-3B84BD304DB3Q35079713-A0DC3DA6-8299-4F45-9547-41BB53BE5CF7Q35167964-1058EDA0-7512-47E8-8066-C47AFFE15FADQ35624275-37E12D1F-5194-40A7-9117-3C98CEFF750DQ35912064-6C8D00C4-2866-4950-B5F6-547F9B1851DDQ36051152-0D4C1E5F-7408-4D11-B491-B0DDBA77A21DQ36060314-25D9E0CE-5FC1-46F8-8364-B16A4B901D76Q36305967-702B5520-F23C-4A11-8203-8333A57C1988Q36366780-DD78D5A3-725F-416F-8C6D-3B6446F2B1B3Q36400251-A6427506-899B-4098-9045-5E83A87079E6Q36932568-096193BF-D889-4536-A727-552BE92AB579Q37003897-B8A8B3FD-A5DA-4202-B57E-FE4D8894D1A6Q37203759-73241505-AF1C-4C4B-A3DD-FF2044F7B5EFQ37217480-FB3BF1F3-929E-47A7-B1BF-720D3B82918EQ37288164-B0DE02C9-5858-436B-9126-CCBF30DA0298Q37395632-00443DE1-C92A-4E15-BE95-811F630F8F3BQ37399627-609F4E77-7500-4290-AB5A-18988BD7697FQ37880260-14849748-F1FF-4F6D-A5E4-47B85AC15534Q38218083-D810022C-551D-4556-B8DC-720454B62B37
P2860
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
@ast
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
@en
type
label
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
@ast
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
@en
prefLabel
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
@ast
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
@en
P2093
P2860
P356
P1476
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
@en
P2093
D Weinshenker
G L Edwards
G W Miller
K G Freeman
K S Rommelfanger
P2860
P304
13804-13809
P356
10.1073/PNAS.0702753104
P407
P577
2007-08-16T00:00:00Z